Sandbox sowminya: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 16: | Line 16: | ||
{{Familytree/end}} | {{Familytree/end}} | ||
</div> | </div> | ||
==Laboratory Findings== | |||
The diagnosis is easily established on histological grounds, but immunophenotyping is encouraged to distinguish follicular lymphoma from a nodular MCL or SLL. | |||
*Diagnosis is established by immunophenotyping using IHC and/or flow cytometry for cell surface marker analysis. | |||
*Follicular lymphoma has a characteristic immunophenotype, which includes CD20+, CD10+, BCL2+, CD23+/-, CD43-, CD5-, CCND1- and BCL6+. Occasional cases of FL may be CD10- or BCL2-.*In patients with BCL2-negative localized disease, the diagnosis of pediatric-type follicular lymphoma may be considered. | |||
*Low-grade follicular lymphoma with a high proliferation index (as determined by Ki-67 immunostaining) has been shown to be associated with an aggressive clinical behavior. | |||
:*There is no evidence, however, that high Ki-67 should guide the selection of therapy. | |||
:*Molecular genetic analysis to detect BCL2 rearrangement, cytogenetics or FISH to identify t(14;18), and immunohistochemistry for Ki-67 may be useful under certain circumstances. | |||
Revision as of 16:51, 22 August 2015
| B-cell neoplasms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CD5+ | CD5- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCND1+ | CCND1- | DLBCL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pleomorphic MCL | DLBCL, NOS CD5+ | CD10+ | CD10- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DLBCL, NOS GCB type | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BCL6+ IRF4/MUM1- | BCL6+ IRF4/MUM1+ | BCL6- IRF4/MUM1+ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DLBCL, NOS GCB type | Non-GCB | Post-GCB | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laboratory Findings
The diagnosis is easily established on histological grounds, but immunophenotyping is encouraged to distinguish follicular lymphoma from a nodular MCL or SLL.
- Diagnosis is established by immunophenotyping using IHC and/or flow cytometry for cell surface marker analysis.
- Follicular lymphoma has a characteristic immunophenotype, which includes CD20+, CD10+, BCL2+, CD23+/-, CD43-, CD5-, CCND1- and BCL6+. Occasional cases of FL may be CD10- or BCL2-.*In patients with BCL2-negative localized disease, the diagnosis of pediatric-type follicular lymphoma may be considered.
- Low-grade follicular lymphoma with a high proliferation index (as determined by Ki-67 immunostaining) has been shown to be associated with an aggressive clinical behavior.
- There is no evidence, however, that high Ki-67 should guide the selection of therapy.
- Molecular genetic analysis to detect BCL2 rearrangement, cytogenetics or FISH to identify t(14;18), and immunohistochemistry for Ki-67 may be useful under certain circumstances.